GLP-1 Pills (2026): Rybelsus, Foundayo & Wegovy Oral — Side-by-Side Comparison of Every Oral GLP-1

Three oral GLP-1 medications matter for US patients in 2026, but only two are FDA-approved: Rybelsus (oral semaglutide, Novo Nordisk — FDA-approved 2019, type 2 diabetes only) and Foundayo (oral orforglipron, Eli Lilly — FDA-approved April 1, 2026, for chronic weight management). A third — Novo Nordisk's high-dose oral semaglutide (1.5 mg / 4 mg / 25 mg / 50 mg strengths) for the weight-management indication, in the OASIS-4 Phase 3 program — is NOT yet FDA-approved as of May 2026. Patients searching for “oral Wegovy” will not find a weight-management-indicated oral semaglutide on US pharmacy shelves. All three are once-daily, but their dosing strictness, food restrictions, indications, formulations, effect sizes, and prices differ materially — anchored to the verbatim DailyMed labels (Rybelsus SetID 27f15fac-7d98-4114-a2ec-92494a91da98; Foundayo SetID 8ac446c5-feba-474f-a103-23facb9b5c62) and the verified PIONEER (PMID 30903796, 31185157) and ATTAIN-1 (PMID 40960239) trials.

What “GLP-1 pill” actually means in 2026

The injectable GLP-1 receptor agonists — Wegovy (semaglutide), Ozempic (semaglutide), Zepbound and Mounjaro (tirzepatide), Saxenda and Victoza (liraglutide), Trulicity (dulaglutide) — dominate the class by prescription volume. For the full FDA-approved-and-investigational drug list see our GLP-1 medication list 2026 full reference. But every one of them requires a needle, refrigeration, and weekly injection technique. The oral GLP-1 category — daily pill, no injection, no refrigerator — has long been a patient priority and a regulatory target. As of 2026 there are two FDA-approved oral GLP-1 receptor agonists:

• Rybelsus (oral semaglutide, Novo Nordisk) — peptide GLP-1 with the SNAC absorption enhancer. FDA-approved September 2019. Indication: type 2 diabetes only.
• Foundayo (oral orforglipron, Eli Lilly) — non-peptide small-molecule GLP-1 receptor agonist. FDA-approved April 1, 2026. Indication: chronic weight management.

A third candidate appears in patient searches and in company-press materials: Novo Nordisk's high-dose oral semaglutide (sometimes called “oral Wegovy”), at strengths reported in trial publications of 1.5 mg, 4 mg, 25 mg, and 50 mg, studied for weight management in the OASIS Phase 3 program. As of May 2026, this product is not yet FDA-approved for weight management. The semaglutide molecule is shared with Rybelsus, but Rybelsus is approved at lower strengths (3 / 7 / 14 / 25 mg) and only for type 2 diabetes. We do NOT make weight-management-indication claims for oral semaglutide in any form, and any pricing references in WLR articles to a “Wegovy oral pill 1.5/4 mg” refer either to promotional inventory tied to the Rybelsus SKU or to channel listings that have not yet matured into a separate FDA-approved Wegovy oral product. Patients should verify the FDA-approved indication on the actual prescription label before assuming any oral semaglutide product is approved for weight loss.

The GLP-1 receptor agonist class extends further — the Trulicity molecule and oral DPP-4 inhibitors (sitagliptin, linagliptin) are sometimes confused with oral GLP-1s. They are not. Trulicity is an injectable Fc-fusion biologic (BLA pathway, see our Trulicity weight-loss evidence review); DPP-4 inhibitors raise endogenous GLP-1 weakly and are not GLP-1 receptor agonists. This article is restricted to the two FDA-approved oral GLP-1 receptor agonists plus the explicit not-approved status of high-dose oral semaglutide for weight management.

Side-by-side comparison: every oral GLP-1

The headline differences in one table — every cell anchored to a primary-source FDA label or to a verified PMID, with cross-trial caveats called out in the deep-dive sections below.

Two cells deserve immediate amplification because they are the most frequent patient-question gaps:

• Rybelsus is NOT approved for weight loss. Patients prescribed Rybelsus by a primary-care clinician for weight management are receiving the medication off-label for that purpose. Insurance coverage for Rybelsus is structured around its T2D indication.
• “Wegovy oral” for weight management does not yet exist as an FDA-approved product — only the injectable Wegovy pen (and the Wegovy HD 7.2 mg pen at higher dose) is FDA-approved for weight management. High-dose oral semaglutide for the weight-management indication is in OASIS-4 Phase 3.

Rybelsus deep-dive (oral semaglutide)

Rybelsus was the first FDA-approved oral GLP-1 receptor agonist (September 2019), and remains the only oral semaglutide product on the US market. The semaglutide molecule is identical to Ozempic (subcutaneous, T2D) and Wegovy (subcutaneous, weight management). What makes Rybelsus unique — and what creates its demanding administration regimen — is the SNAC absorption enhancer (sodium N-(8-[2-hydroxybenzoyl]amino)caprylate), which transiently protects the semaglutide peptide from gastric pH and proteolysis long enough for absorption across the stomach epithelium. Even with SNAC, the bioavailability is on the order of 1% — meaning oral doses are roughly two orders of magnitude higher than bioequivalent subcutaneous doses (3-25 mg PO vs 0.25-2.4 mg SC).

Indication and dosing — verbatim

Per §1 INDICATIONS AND USAGE of the Rybelsus DailyMed label (SetID 27f15fac-7d98-4114-a2ec-92494a91da98), Rybelsus is indicated:

• As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• To reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease — added October 2025 per the SOUL trial (7 mg + 14 mg only)

Rybelsus is NOT FDA-approved for chronic weight management. Patients seeking weight loss are not the labeled population. Off-label prescribing for weight loss occurs but is not the cleaner path; the weight-management-indicated brands (Wegovy, Zepbound, Foundayo, Saxenda) are.

Per §2 DOSAGE AND ADMINISTRATION, the dosing ladder is:

• 3 mg orally once daily for 30 days (a starting / acclimation dose; not therapeutic)
• 7 mg orally once daily after the 30-day starting dose
• 14 mg orally once daily, after at least 30 days on 7 mg, if additional glycemic control is needed
• 25 mg orally once daily — added per recent label expansion in some markets; 25 mg is not yet universally listed in every Rybelsus PI revision

The Rybelsus food restriction (verbatim — strict, material, load-bearing)

The single most important practical fact about Rybelsus is the §2 administration rule. From the verbatim DailyMed label:

“Take RYBELSUS at least 30 minutes before the first food, beverage, or other oral medications of the day with no more than 4 ounces of plain water only. Taking with more than 4 ounces of water, with food, or with other oral medications will reduce semaglutide absorption.”

This is the strictest administration rule in the entire GLP-1 class. Practical implications most patients underestimate:

• Coffee, tea, juice, milk, electrolyte drinks, or any other beverage in the morning will reduce absorption. Plain water only — and no more than 4 ounces. The Rybelsus PI explicitly does not waive this for any beverage.
• Other morning medications (statins, SSRIs, levothyroxine, blood pressure pills, oral contraceptives) cannot be taken in the same window. Rybelsus must be the first thing in the day; the 30-minute wait must elapse before any other oral medication.
• Breakfast must wait at least 30 minutes after the dose. Some patients extend this to 45-60 minutes for safety margin; the label minimum is 30. A patient who routinely eats within 15-20 minutes of the dose is materially underdosed.
• Weekend / travel mornings are the highest-risk failure point. Patients who skip the dose because they want coffee immediately — or take it inconsistently because the fasted-morning routine breaks on weekends — see reduced steady-state concentrations and reduced glycemic effect.

The food restriction is mechanistic: the SNAC enhancer creates a brief absorption window in the stomach that is defeated by gastric distension, food, or fluid volume. Patients who tell their prescriber “I take Rybelsus with my coffee” are taking a much-reduced effective dose.

Trial efficacy — PIONEER program

Rybelsus was developed through the PIONEER (Peptide Innovation for Early Diabetes Treatment) Phase 3 program. The trials measured HbA1c reduction and CV outcomes — not weight loss as a primary endpoint. Two anchor publications:

• PIONEER 3 (Rosenstock et al., JAMA 2019, PMID 30903796): 78-week T2D trial showing oral semaglutide 7 mg and 14 mg produced significantly greater HbA1c reduction than sitagliptin 100 mg, with body-weight reductions of 2.7 kg (7 mg) and 4.5 kg (14 mg) at week 26 — modest weight effect relative to subcutaneous semaglutide at the same molecular dose-equivalent.
• PIONEER 6 (Husain et al., NEJM 2019, PMID 31185157): Cardiovascular safety trial of oral semaglutide vs placebo in T2D patients at high CV risk. The composite MACE endpoint occurred in 3.8% (semaglutide) vs 4.8% (placebo) over a median 15.9 months — non-inferior for safety. This trial established the foundation that supported the October 2025 CV-risk-reduction indication added to the Rybelsus label (limited to 7 mg + 14 mg, per the SOUL trial as well).

Notably absent from the Rybelsus trial program: a weight-management Phase 3 trial. Novo Nordisk pursued the weight-management indication for oral semaglutide separately — at higher doses (25 / 50 mg) under the OASIS program — which is the candidate sometimes called “Wegovy oral” (covered below).

Foundayo deep-dive (oral orforglipron)

Foundayo received FDA approval on April 1, 2026 — the first oral GLP-1 receptor agonist FDA-approved for chronic weight management, and the first non-peptide small-molecule GLP-1 RA in the entire class. Eli Lilly developed orforglipron specifically to bypass the peptide-stability problem that forces Rybelsus into its strict fasted-morning regimen. Because orforglipron is a small organic molecule (not a peptide), it survives gastric pH, requires no absorption enhancer, and has no food-restriction requirement. The clinical and practical consequences are large.

Indication and dosing — verbatim

Per §1 INDICATIONS AND USAGE of the Foundayo DailyMed label (SetID 8ac446c5-feba-474f-a103-23facb9b5c62), Foundayo is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbid condition. Foundayo is not FDA-approved for type 2 diabetes glycemic control as of May 2026 (the ATTAIN-2 T2D + obesity trial supports the molecule's glycemic effect, but the T2D indication has not yet been added to the label).

Per §2 DOSAGE AND ADMINISTRATION, the dosing ladder is:

“The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily. After at least 30 days on the 2.5 mg dosage, increase the dosage to 5.5 mg once daily. The dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability. The maximum dosage of FOUNDAYO is 17.2 mg once daily.”

Six discrete dose strengths, each ≥30 days. The minimum time-to-top-dose is approximately 5 months. For the full calendar walk-through see our Foundayo week-by-week titration guide.

Foundayo food rule (verbatim) — the contrast with Rybelsus

Per §2 of the Foundayo label, verbatim:

“Take FOUNDAYO orally once daily, with or without food.”

That single sentence is the largest practical advantage of Foundayo over Rybelsus for many patients. There is no fasted morning window, no 4-ounce water cap, no 30-minute pre-food wait, no pre-medication sequencing constraint. Patients can take Foundayo with coffee, with breakfast, with their morning blood-pressure pill, with a glass of orange juice — none of those reduce absorption. The label adds two administration constraints, both verbatim:

• “Swallow tablets whole. Do not break, crush, or chew.”
• “Do not take more than one tablet per day.”

Trial efficacy — ATTAIN program

The Foundayo Phase 3 program — ATTAIN — produced two anchor publications by April 2026:

• ATTAIN-1 (Wharton et al., NEJM 2025, PMID 40960239): 72-week trial in adults with obesity or overweight (without T2D). Per §14 CLINICAL STUDIES of the DailyMed label, orforglipron 17.2 mg produced −11.1% body weight vs −2.1% placebo (Δ −9.0%) at 72 weeks; 9 mg produced −8.3%; 5.5 mg produced −7.4%. Baseline weight 103.9 kg.
• ATTAIN-2 (Horn et al., Lancet 2026, PMID 41275875): 72-week trial in adults with obesity or overweight plus type 2 diabetes. Demonstrated weight loss and HbA1c reduction. Has not yet been used to add a T2D indication to the Foundayo label as of May 2026.

These are the ONLY published Phase 3 weight-loss-as-primary- endpoint trials of any oral GLP-1 receptor agonist as of May 2026. PIONEER (Rybelsus) measured HbA1c. OASIS (high-dose oral semaglutide for weight management) is the parallel program, but its weight-management formulation is not yet FDA-approved (next section).

Wegovy oral semaglutide for weight management — current regulatory status

The OASIS Phase 3 program — Novo Nordisk's weight-management trial program for high-dose oral semaglutide — has produced multiple readouts at trial doses of 1.5 mg, 4 mg, 25 mg, and 50 mg. OASIS-1 published in 2023 showed oral semaglutide 50 mg produced approximately 15.1% body-weight reduction at 68 weeks vs placebo — weight-management-indication-relevant efficacy at a substantially higher dose than the 14 mg approved for T2D under Rybelsus. OASIS-4 extended the program. As of May 2026, none of these dose strengths is FDA-approved for the chronic-weight-management indication. The active weight-management semaglutide products on the US market are the injectable Wegovy pen (subcutaneous, FDA-approved 2021) and the Wegovy HD 7.2 mg pen (higher-dose injection, also subcutaneous).

Pricing references in earlier WLR articles to a “Wegovy oral pill 1.5 / 4 mg” at $149/month through NovoCare are channel-listing-side references to oral semaglutide inventory; the indication on the dispensed prescription label remains type 2 diabetes (Rybelsus brand). Until the FDA approves a high-dose oral semaglutide for weight management, no patient should interpret an oral semaglutide prescription as an FDA-approved weight-management therapy. The cleaner FDA-approved oral weight-loss path in 2026 is Foundayo.

Cross-comparison: which oral GLP-1 produces the most weight loss?

This question requires immediate caveats. There is no head-to-head trial comparing Rybelsus to Foundayo, or Foundayo to high-dose oral semaglutide. Cross-trial comparisons rest on different patient populations, different baseline weights, different durations, different placebo run-ins, and different adherence profiles. With those caveats, the best available trial-anchored weight-loss numbers for each oral agent:

Read carefully:

• Foundayo at the FDA-labeled top dose (17.2 mg) is the best FDA-approved oral GLP-1 weight-loss option. ATTAIN-1 −11.1% at 72 weeks is the only labeled weight-management efficacy claim available for an oral GLP-1 in May 2026.
• Rybelsus weight-loss numbers are from T2D trials, not weight-management trials. Patients on Rybelsus generally see modest weight loss as a secondary effect, but the trial program never targeted the weight-management indication and the population was T2D- enriched (different baseline metabolic profile).
• High-dose oral semaglutide 50 mg in OASIS-1 produced larger numerical weight loss than Foundayo 17.2 mg in ATTAIN-1 — but cross-trial comparison without harmonized populations is not regulatory-grade evidence, AND the high-dose oral semaglutide product is not yet FDA-approved for weight management. Patients cannot prescribe themselves into a non-approved product.
• For context vs injectable GLP-1s: Wegovy 2.4 mg (subcutaneous) produced ~−14.9% in STEP-1 over 68 weeks; Zepbound 15 mg (subcutaneous) produced ~−20.9% in SURMOUNT-1 over 72 weeks. The injectables produce greater weight loss than any FDA-approved oral GLP-1 today.

The indication mismatch: Rybelsus is T2D-only

Patients regularly conflate “oral semaglutide” with “oral Wegovy.” They are not the same product. Semaglutide is the molecule; Wegovy and Ozempic and Rybelsus are three different brand-name products with different routes, doses, and different FDA-approved indications. Insurance formularies treat them differently. Prior-authorization requirements differ. Even prescribers conflate them — in Cigna's CNF 360 GLP-1 prior-authorization policy, for example, “Rybelsus does NOT satisfy the step” when the policy requires a non-Rybelsus oral antidiabetic in the 130-day lookback (see our Cigna GLP-1 prior-authorization guide). The brand / molecule / indication confusion has downstream cost and access consequences.

The cleanest mental model:

• Want oral semaglutide for type 2 diabetes? That is Rybelsus. FDA-approved 2019. Strict food restriction. Strengths 3 / 7 / 14 mg (plus 25 mg per recent label expansion).
• Want oral semaglutide for weight management? As of May 2026, that product is not FDA-approved. High-dose oral semaglutide is in OASIS-4 Phase 3. Off-label Rybelsus prescribing for weight loss does happen but is not the labeled population.
• Want an FDA-approved oral GLP-1 for weight management? That is Foundayo. FDA-approved April 2026. No food restriction. Six dose strengths. ATTAIN-1 anchor: −11.1% at 17.2 mg over 72 weeks.
• Want an injectable GLP-1 for weight management? That is Wegovy (semaglutide), Zepbound (tirzepatide), or Saxenda (liraglutide). Larger top-line efficacy than any oral, but injection-required.

Cost and channels

Anchor cash-pay prices verified to the WLR pricing dataset, 2026-05-09:

• Foundayo (LillyDirect / Amazon Pharmacy): $149/month cash-pay. With Lilly's commercial savings card, eligible commercially insured patients can pay as little as $25/month.
• Rybelsus: Cash-pay price varies by channel; promotional pricing of $149/month has appeared in some channels tied to Rybelsus inventory under NovoCare/Novo Nordisk programs. Insurance coverage is structured around the T2D indication; weight-management off-label use is typically not covered.
• High-dose oral semaglutide for weight management: N/A — not FDA-approved, not on the US market for weight management as of May 2026.

Both FDA-approved oral GLP-1s are room-temperature stable — no refrigerator, no needles, no sharps container. That is the practical reason patients seek them out, even when the weight-loss ceiling is lower than the injectables. For the full cash-pay channel walkthrough across every GLP-1, see our Wegovy / GLP-1 cash-pay coupon channel guide and the live GLP-1 compounded pricing index.

Bottom line

Three oral GLP-1 stories matter in 2026 — but only two FDA-approved products. Rybelsus (oral semaglutide, 2019, T2D-only) is the older option, with the strictest food restriction in the GLP-1 class — take at least 30 minutes before the first food, beverage, or other oral medications, with no more than 4 ounces of plain water — and a top labeled dose (14 mg, with 25 mg per label expansion) that produces modest weight loss as a secondary effect in T2D trials, NOT a labeled weight-management outcome. Foundayo (oral orforglipron, April 2026, weight-management-indicated) is the new FDA-approved oral for chronic weight management — non-peptide small molecule, no food restrictions, six dose strengths from 0.8 mg to 17.2 mg, ATTAIN-1 −11.1% body weight at the top dose over 72 weeks. Novo Nordisk's high-dose oral semaglutide for weight management (OASIS-4 Phase 3) is NOT yet FDA-approved as of May 2026 — patients cannot fill an FDA-approved oral semaglutide prescription for the weight-management indication today; the labeled oral semaglutide product (Rybelsus) is for type 2 diabetes. Cross-trial weight-loss comparison favors Foundayo 17.2 mg over Rybelsus 14 mg by a wide margin for the weight-management use case, BUT injectable Wegovy 2.4 mg (~−14.9% STEP-1) and Zepbound 15 mg (~−20.9% SURMOUNT-1) produce more top-line weight loss than any oral GLP-1 FDA-approved today. Choosing between them is a prescriber conversation anchored to indication, food-restriction tolerance, GI tolerability, target weight loss, and access channel.

Related research

• Rybelsus alternatives: when oral semaglutide isn't working — switching to Foundayo, Wegovy, or compounded
• Foundayo vs Wegovy vs Zepbound full comparison
• Foundayo week-by-week titration guide
• Foundayo ↔ Zepbound switch dose-equivalence guide
• Diabetes vs weight-loss GLP-1 disambiguation
• Brand-name cheat sheet (Wegovy / Ozempic / Zepbound / Mounjaro / Rybelsus / Foundayo)
• How to take Foundayo (practical daily guide)
• Wegovy / GLP-1 cash-pay coupon channel guide
• GLP-1 medications pillar (every approved + investigational agent)